Trials / Recruiting
RecruitingNCT06083870
An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- Sponsor
- Lu Shun · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety, tolerability, pharmacokinetics and efficacy of Oba01 for injection in patients with DR5 positive LA/mNSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oba01 | Oba01 0.15, 0.5, 0.75, 1.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle |
Timeline
- Start date
- 2023-12-13
- Primary completion
- 2025-07-01
- Completion
- 2026-07-01
- First posted
- 2023-10-16
- Last updated
- 2023-12-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06083870. Inclusion in this directory is not an endorsement.